Coherus Oncology, Inc. (CHRS)

Coherus Oncology's stock has been influenced by its strategic shift to oncology, including the divestiture of its UDENYCA franchise in April 2025 for up to $558.4 million. LOQTORZI's patient demand increased by over 15% in Q1 2025 compared to Q4 2024, and it received Preferred status for NPC in the NCCN guidelines in November 2024. Recent earnings reports include Q4 2024 on March 10, 2025, Q1 2025 on May 12, 2025, and Q2 2025 on August 7, 2025. The stock price increased after biosimilar sales but has since declined.

While detailed information is limited, there was a "seasonal inventory drawdown" for LOQTORZI in Q1 2025. Patient demand for LOQTORZI grew by over 15% in Q1 2025 compared to the previous quarter, indicating robust underlying demand despite potential seasonal fluctuations.

Coherus Oncology, Inc. is a biopharmaceutical company focused on developing cancer immunotherapies, with its main product being LOQTORZI (toripalimab) for nasopharyngeal carcinoma (NPC). The company is also advancing immuno-oncology candidates like CHS-114 and Casdozokitug in clinical trials for various cancers. Coherus divested its biosimilar assets, including UDENYCA, CIMERLI, and YUSIMRY, to concentrate on its oncology pipeline.

Coherus Oncology, Inc. is headquartered in Redwood City, California, and has employees across North America and Europe. The company has commercialization partnerships with global pharmaceutical companies in Europe, Asia, and Latin America.

Coherus Oncology's brand reputation has been shaped by its strategic pivot to a pure-play oncology company, including the divestiture of biosimilar assets and rebranding in May 2025. This shift is viewed positively, emphasizing the company's focus on innovative cancer therapeutics.

Institutional investors hold approximately 47.50% of Coherus Oncology, Inc.'s common stock, with major shareholders including Vanguard Group Inc., BlackRock, Inc., and Tang Capital Management Llc. Insiders own approximately 1.13% of the company's stock.